Table 1

Studies included in systematic review

Study
(country)
n (male)Mean sizeMean follow-upMean ageLocationLocal recurrenceMetastasesRisk of bias*
Bowe et al3 (UK)49 (45)23.5 mm (median)22.4 months80 (median)32 scalp
5 forehead
3 ear
3 cheek
2 nose
2 lower leg
1 temple
1 lower lip
6/41
(6 clear margins)
1/41
(1 death)
Moderate
7/41
Cesinaro et al4 (Italy)713 months3/70/7
(0 deaths)
Low
3/7
Helbig et al5 † (Germany)25 (19)783 head/neck
2 shoulder
0 deaths from 1 MiTF-expressing PDS case with follow-upHigh
Jasper et al6 (Canada)206/202/20Moderate
Klein et al7† (Germany)28 (23)80 (median)26 head/neck
2 shoulder
5/28Moderate
Lonie et al2 (Australia)27 (23)46.4 months79.2717 scalp
7 face
2 ear
1 torso
2/26
(1 positive, 1 close margin)
1/27
(1 death)
Low
3/27
Miller et al8 (UK)32 (27)25 mm24 months (median)8122 scalp
4 forehead
2 ear
2 temple
1 eyebrow
1 forearm
8/29
(7 incomplete removal)
3/29
(0 deaths)
Moderate
8/29
Miller et al9 (USA)172/20/2High
2/2
Müller et al10 (Germany)19 (15)6.75 cm281.1616 head
2 face
1 upper extremity
2/190/19High
2/19
Nonaka and Bishop11 (Japan)34>2 years1/34 death (positive margin, metastasis)Moderate
Persa et al12 (Europe)92 (80)20 mm18 months81 (median)76 scalp
9 trunk
7 extremities
18/928/92Low
26/92
Ríos-Viñuela et al13‡ (Spain)16 (14)25.63
mm (n=15)
25.88 months80.4310 scalp
1 forehead
2 nose
2 ear
1 temple
12/16 (8 positive margins)3/16 (2 deaths)Low
12/16
Tardío et al14 (Spain)18 (9)22 mm40 months819 scalp
5 forehead
1 nose
1 eyebrow
1 cheek
1 temple
3/15
(3 positive margins)
3/15
(3 deaths)
Moderate
5/15
Thum et al15 § (UK)3 (3)31.67
mm
3 months792 scalp
1 temple
0 recurrences or deaths from 2 pseudovascular PDS cases with follow-upModerate
Wang et al16 ¶ (USA)6 (6)11 mm48.6 months613 scalp
2 temple
1 ear
4 recurrences and 4 deaths from 6 metastatic PDS casesLow
Total331 (199/237 male)21.47
mm
13–46.4 months80.64156/218 scalp
33/237 face
50/25118/252
(6/174 deaths)
5 low
7 moderate
3 high
56/232
  • *Rated using the modified Newcastle-Ottawa Scale for case series from Haffar et al.21

  • †Results not pooled with others due to overlap with cohort from Persa et al.12

  • ‡Results not pooled with others as study cohort was primarily composed of recurrent PDS referred from other institutions.

  • §Results not pooled with others as study examines a subset cohort from Miller et al8 of pseudovascular PDS.

  • ¶Results not pooled with others as study examined metastatic PDS only.

  • MiTF, Microphthalmia-associated transcription factor; PDS, pleomorphic dermal sarcoma.